East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2474)
07/06/2023

Indication

In combination with lenvatinib, for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation. SMC restriction: tre...

In combination with lenvatinib, for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.

Therapeutic Area

Malignant disease and immunosuppression

Status Description

Routinely available in line with national guidance

Formulation

25mg/mL concentrate for solution for infusion

Comments

June 2023 - Routinely available in line with national guidance. Included on the ERF for Specialist Use only.

Link to Advice

SMC2474

Advice Published

10/10/2022

SMC Submission Type

Full

SMC Status

Restricted